AI predicts immunotherapy response in advanced stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial uses artificial intelligence to analyze CT scans, blood, and tumor tissue to predict how well your cancer will respond to chemotherapy and immunotherapy before surgery. It aims to personalize treatment for locally advanced stomach or gastroesophageal junction cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have stomach or gastroesophageal junction adenocarcinoma that is locally advanced (stages T3-4a, N+, M0).
- You are scheduled to receive chemotherapy (like SOX or XELOX) combined with a PD-1 inhibitor (like sintilimab, tislelizumab, or camrelizumab) before surgery.
- You have a CT scan of your abdomen with contrast done before treatment.
- You are willing to provide blood samples and tumor tissue for testing.
- Your overall health is good (ECOG 0 or 1), and your organs are working well enough for chemotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three treatments—an immunotherapy drug (sintilimab), a blood-vessel-blocking drug (bevacizumab), and chemotherapy—for advanced stomach cancer that cannot be surgically removed but has elevated AFP levels (a tumor marker). The goal is to shrink the tumor and potentially make it operable.
This study tests whether an AI tool can predict how well stomach cancer responds to chemotherapy before surgery. It uses CT scans and biopsy images taken before treatment starts to see if the AI can help guide future care.
This trial uses artificial intelligence to analyze CT scans and predict how well esophageal cancer responds to chemotherapy combined with immunotherapy before surgery. The goal is to help doctors personalize treatment for better outcomes.
This trial tests a computer-based model that uses CT scans, endoscopic images, and biopsy tissue to predict how well stomach cancer will respond to chemotherapy given before surgery. The goal is to help doctors choose the best treatment for each patient.
This study uses artificial intelligence to predict whether stomach cancer has spread to nearby lymph nodes. By analyzing your CT/MRI scans and biopsy results before surgery, the AI may help doctors plan your treatment more precisely.
This study looks at markers in your tumor to predict how well immunotherapy might work for you. It aims to create a model that helps doctors choose the best treatment for advanced gastric cancer.
Hear when a new Locally Advanced Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.